Staff Members - Benha University
Can trajectory nor-epinephrine infiltration reduce blood loss during percutaneous nephrolithotomy? A double-blinded randomized controlled trial
• 2023
Publication Information
Authors
Waleed El-Shaer,1 Mohamed Salah Haggag,2 Alaa Elshaer,1
Islam Shaboob,3 Wael Kandeel,1
Basheer Elmohamady,1 Dina Saad Abdelmotaleb4
and Sally Abdel-Lateef
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Purpose: To determine the efficacy and safety of trajectory infiltration with 1:150 000
Norepinephrine (NE) in reducing blood loss during percutaneous nephrolithotomy (PCNL).
Materials and methods: This is a prospective randomized double-blinded placebocontrolled trial. In all, 140 consecutive patients underwent PCNL for the management of
large renal calculi. They were randomly assigned (1:1) to one of either study groups, the
NE-PCNL group (70 patients whose PCNL-trajectory was infiltrated by NE) or the Placebo
group (saline PCNL) (70 patients whose PCNL tracts were infiltrated by normal saline).
Procedure-related blood loss (the primary outcome) was assessed and statistically
analyzed. Also, all other procedure-related events and complications were recorded and
compared.
Results: The median blood loss was 378 ml (IQR: 252–504) in the NE-PCNL group
versus 592 ml (IQR: 378–756) in the S-PCNL group (p < 0.0001). In addition, Hemoglobin
and Hematocrit deficits were lower in NE-PCNL (p < 0.05). Patients who were
randomized to the NE-PCNL group had a higher immediate stone-free rate (SFR) (80%)
compared with those of the S-PCNL group (70%) (p = 0.034). However, no statistical
differences were found in the final SFR. The reported overall complications between the
2 groups were similar (p > 0.05). Indeed, bleeding-related complications were 1 (1.4%)
versus 10 (14.3%) for NE-PCNL and S-PCNL, respectively (p = 0.009).
Conclusions: Trajectory infiltration of PCNL tracts by NE was found to be effective and
safe in mitigation of PCNL-related blood loss. This step is a timeless and cost-effective as
NE is readily available in surgical theaters and of very low cost
Norepinephrine (NE) in reducing blood loss during percutaneous nephrolithotomy (PCNL).
Materials and methods: This is a prospective randomized double-blinded placebocontrolled trial. In all, 140 consecutive patients underwent PCNL for the management of
large renal calculi. They were randomly assigned (1:1) to one of either study groups, the
NE-PCNL group (70 patients whose PCNL-trajectory was infiltrated by NE) or the Placebo
group (saline PCNL) (70 patients whose PCNL tracts were infiltrated by normal saline).
Procedure-related blood loss (the primary outcome) was assessed and statistically
analyzed. Also, all other procedure-related events and complications were recorded and
compared.
Results: The median blood loss was 378 ml (IQR: 252–504) in the NE-PCNL group
versus 592 ml (IQR: 378–756) in the S-PCNL group (p < 0.0001). In addition, Hemoglobin
and Hematocrit deficits were lower in NE-PCNL (p < 0.05). Patients who were
randomized to the NE-PCNL group had a higher immediate stone-free rate (SFR) (80%)
compared with those of the S-PCNL group (70%) (p = 0.034). However, no statistical
differences were found in the final SFR. The reported overall complications between the
2 groups were similar (p > 0.05). Indeed, bleeding-related complications were 1 (1.4%)
versus 10 (14.3%) for NE-PCNL and S-PCNL, respectively (p = 0.009).
Conclusions: Trajectory infiltration of PCNL tracts by NE was found to be effective and
safe in mitigation of PCNL-related blood loss. This step is a timeless and cost-effective as
NE is readily available in surgical theaters and of very low cost